Second-generation antidepressant
The second-generation antidepressants are a class of antidepressants characterized primarily by the era of their introduction, approximately coinciding with the 1970s and 1980s, rather than by their chemical structure or by their pharmacological effect. As a consequence, there is some controversy over which treatments actually belong in this class.
The term "third generation antidepressant" is sometimes used to refer to newer antidepressants,[1] from the 1990s and 2000s, often selective serotonin reuptake inhibitors (SSRIs) such as; fluoxetine (Prozac), paroxetine (Paxil) and sertraline (Zoloft), as well as some non-SSRI antidepressants such as mirtazapine, nefazodone, venlafaxine, duloxetine and reboxetine. However, this usage is not universal.
Examples
This list is not exhaustive, and different sources vary upon which items should be considered second-generation.
- Amineptine
- Amoxapine
- Bupropion
- Iprindole
- Maprotiline
- Medifoxamine
- Mianserin
- Nomifensine
- Tianeptine
- Trazodone
- Viloxazine
References
- ^ Olver JS, Burrows GD, Norman TR (2001). "Third-generation antidepressants: do they offer advantages over the SSRIs?". CNS Drugs. 15 (12): 941–54. doi:10.2165/00023210-200115120-00004. PMID 11735614.
External links
- Second-Generation+Antidepressive+Agents at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
- Diagrams at toxlab.co.uk
- Overview at sagepub.com
- Overview at psyweb.com
- Overview at sciencedaily.com
- Overview at sabryabdelfattah.tripod.com
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |